Search

Recursion Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

3.56 0.85

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.4699999999999998

Max

3.8

Belangrijke statistieken

By Trading Economics

Inkomsten

12M

-119M

Verkoop

11M

19M

EPS

-0.22

Winstmarge

-641.634

Werknemers

600

EBITDA

10M

-102M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+88.45% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

334M

2.4B

Vorige openingsprijs

2.71

Vorige sluitingsprijs

3.56

Recursion Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 nov 2026, 21:02 UTC

Macro Event

Recursion Pharmaceuticals, Inc. shares fell sharply today, continuing a decline since Monday's close, amid mixed signals from recent macroeconomic data releases.

9 nov 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. shares declined modestly in after-market trading, retracing from an earlier uptick and reaching a low in its one-month range.

6 nov 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. is trading higher in after-market hours, reaching its highest level since Friday's close.

5 nov 2026, 23:22 UTC

Correlated Moves

Recursion Pharmaceuticals, Inc. is trading lower in after-market hours, in line with a broader market decline and losses in the ARK Genomic Revolution ETF (ARKG).

4 nov 2026, 21:04 UTC

Correlated Moves

Recursion Pharmaceuticals shares are rising during Wednesday's session, following a broader biotechnology sector increase and strong gains in the SPDR S&P Biotech ETF.

3 nov 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. is moving higher in after-market hours, reflecting broader market gains amid strong economic data influencing Federal Reserve policy.

2 nov 2026, 23:02 UTC

Social Media
News

Recursion Pharmaceuticals appointed Fred Hassan as Chair of the Board, effective October 31, 2026, and reported positive Phase 2 data for REC-4881.

31 okt 2026, 00:01 UTC

Recursion Pharmaceuticals, Inc. is trading lower in after-market hours, having declined from Friday's close amid volatility and stabilization near its one-month range.

30 okt 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. declined during after-market hours, with cumulative returns falling since Friday's close after briefly peaking earlier in the session.

29 okt 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. shares declined during after-market hours on Thursday, breaking a trend of higher daily closes established earlier in the week.

28 okt 2026, 23:02 UTC

Recursion Pharmaceuticals, Inc. is trading lower in after-market hours, reflecting the broader market's decline and retracing from an earlier session high.

27 okt 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. is declining in after-market hours, marking a significant retracement from recent highs after finishing higher for three consecutive sessions.

26 okt 2026, 20:07 UTC

Recursion Pharmaceuticals Inc shares are advancing, having reached an early peak but ultimately settling lower near the lower end of their one-month range.

24 okt 2026, 00:01 UTC

Recursion Pharmaceuticals Inc shares are trading lower in after-market hours, having retraced from a brief peak earlier in the session.

23 okt 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

22 okt 2026, 23:02 UTC

Recursion Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving lower since Thursday's close and reaching its lowest point of the day.

21 okt 2026, 23:51 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading lower in after-market hours, reflecting broader market trends and positioning below its 20-day moving average.

20 okt 2026, 23:02 UTC

Social Media

Recursion Pharmaceuticals Inc shares are trading modestly lower in after-market hours, with approximately $561 million in cash at the end of the quarter.

19 okt 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is advancing in after-market trading, maintaining an upward trajectory since Monday's close.

17 okt 2026, 00:01 UTC

Recursion Pharmaceuticals Inc shares advanced modestly higher during after-market hours on Friday, diverging from the recent trend of higher daily closes.

16 okt 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are modestly higher in after-market trading.

15 okt 2026, 20:03 UTC

News
Event
Macro Event

Recursion Pharmaceuticals announces a $200 million oversubscribed follow-on offering and positive updates on drug candidate REC-4881, achieving a 47% median reduction in polyp burden.

14 okt 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, aligning with broader market losses amid rising inflation concerns and geopolitical tensions affecting oil supply.

13 okt 2026, 23:06 UTC

Recursion Pharmaceuticals Inc is trading modestly higher in after-market hours following Tuesday's close.

12 okt 2026, 20:02 UTC

Recursion Pharmaceuticals Inc shares are sharply lower, continuing a downward trend since Friday, despite an early spike in today's trading session.

10 okt 2026, 00:01 UTC

Recursion Pharmaceuticals Inc shares advanced during after-market hours on Friday, despite earlier pulling back from a session high.

9 okt 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is trading modestly higher in after-market hours, recovering from an earlier decline while remaining well above its 20-day moving average.

8 okt 2026, 20:01 UTC

News
Correlated Moves

Recursion Pharmaceuticals faces downward pressure amid significant insider transactions, including a 50k share sale by Director Borgeson Blake on October 6.

7 okt 2026, 23:05 UTC

Recursion Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of three consecutive sessions finishing lower since Wednesday's close.

6 okt 2026, 20:02 UTC

Correlated Moves
Social Media
News

Recursion Pharmaceuticals Inc. shares fell amid sector declines, with attention on upcoming Phase 2 data for REC-4881 and ongoing trials for other candidates.

Peer Vergelijking

Prijswijziging

Recursion Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

88.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.633 USD  88.45%

Hoogste 8 USD

Laagste 5.9 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Recursion Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat